Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, single center, phase III clinical trial comparing the efficacy
and safety of four cycles of epirubicin combined with cyclophosphamide followed by four
cycles of docetaxel (EC*4-T*4) verses 6 cycles of weekly paclitaxel combined with carboplatin
(PCb*6) in the adjuvant chemotherapy of non-triple negative breast cancer patients. The study
is divided in to 2 branches: PANSY-1 and PANSY-2. PANSY-1 is a study of hormone receptor
(HR)-positive/human epidermal growth factor receptor-2 (HER2)-negative patients with ≥4
positive lymph node, while PANSY-2 is a study of HER2-positive patients with ≥1 positive
lymph node.